Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin...Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or death.The primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and safety.This study was registered in Clinical Trials.gov(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)group.As of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)months.ORRof responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,respectively.The stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,or recurrent non-squamous NSCLC patients in the first-line setting.展开更多
Objective:To explore the effect of carbon ion radiotherapy(CIRT)on the bone marrow adjacent to or within the treatment fields,and to observe the bone marrow toxicities after CIRT alone.Methods:Twenty-one patients with...Objective:To explore the effect of carbon ion radiotherapy(CIRT)on the bone marrow adjacent to or within the treatment fields,and to observe the bone marrow toxicities after CIRT alone.Methods:Twenty-one patients with malignant tumors of different body parts and treated with CIRT in Heavy Ion Center,Wuwei Cancer Hospital were analyzed retrospectively.The data of white blood cells,neutrophils,hemoglobin,platelets,lymphocytes and globulin before treatment,7,14 and 28 d during treatment,and 1 and 3 months after treatment were collected.Hematological toxicities were measured according to the Common Terminology Criteria for Adverse Events(CTCAE,Version 4.03)criteria.Dose-volume histogram parameters were obtained for all patients and analyzed for their correlation with myelosuppression.Univariate analysis was performed for patients’sex,age group,tumor site,radiation dose,and Karnofsky performance score(KPS)was used as an independent factor to find predictors factors for the risk of myelosuppression.Results:CIRT minimized the dose radiated to the bone marrow.Overall,volume receiving 3 GyE(V3)or more of the bone marrow were less than 0.5%,especially V5 less than 0.1%.No patients treated with carbon ion radiotherapy developed grade III or IV myelosuppression.Seven patients(33.3%)developed grade I myelosuppression and one patient(4.8%)developed grade II myelosuppression,and most of them showed reduced white blood cell counts.There were no significant differences in hemoglobin and globulin levels before and after CIRT.Univariate analysis did not find any statistically significant predictors for myelosuppression.Conclusions:CIRT is effective in preserving bone marrow function regardless of tumor site.Patients receiving CIRT alone have a low incidence of grade III myelosuppression and a mild effect on globulins.There was no significant correlation between occurrence of myelosuppression and the dose and site irradiated by CIRT.展开更多
基金China National Major Project for New Drug Innovation,Grant/Award Number:2017ZX09304015Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(CIFMS),Grant/Award Number:2016-I2M-1-001。
文摘Background:Previous studies have demonstrated the preclinical pharmacological and toxicological consistency,and clinical pharmacokinetic equivalence of bevacizumab biosimilar LY01008 with reference bevacizumab(Avastin).This randomized controlled trial aimed to compare the efficacy and safety of LY01008 with Avastin in first-line treatment of Chinese patients with advanced or recurrent non-squamous non-small cell lung cancer(NSCLC).Methods:StageⅢB-ⅣNSCLC patients with evaluable lesions,good physical status,and adequate organ functions from 67 centers across China were randomized in a ratio of 1:1 to receive LY01008 or Avastin 15 mg/kg intravenously in combination with paclitaxel/carboplatin(combined treatment)for 4-6 cycles,followed by maintenance monotherapy with LY01008 until disease progression,intolerable toxicity,or death.The primary endpoint was objective response rate(ORR)in accordance with Response Evaluation Criteria in Solid Tumors(RECIST)version 1.1 confirmed by independent radiological review committees(IRRC).Secondary endpoints included disease control rate(DCR),duration of response(DoR),progression-free survival(PFS),overall survival(OS),and safety.This study was registered in Clinical Trials.gov(NCT03533127).Results:Between December 15^(th),2017,and May 15^(th),2019,a total of 649 patients were randomized to the LY01008(n=324)or Avastin(n=325)group.As of September 25th,2019 for primary endpoint analysis,589 patients received ORR evaluation,with a median number of combined treatment cycles of 5(range 1-6)andmedian duration of treatment of 3.0(range 0.0-5.1)months.ORRof responseevaluable patients in the LY01008 and Avastin groups were 48.5% and 53.0%,respectively.The stratified ORR ratio was 0.91(90%CI 0.80-1.04,within the prespecified equivalence margin of 0.75-1.33).Up to May 15^(th),2020,with a median follow-up of 13.6(range 0.8-28.4)months,no notable differences in DCR,median DoR,median PFS,median OS,and 1-year OS rate were observed between the LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,LY01008 and Avastin groups.There were no clinically meaningful differences in safety and immunogenicity across treatment groups.Conclusions:LY01008 demonstrated similarity to Avastin in terms of efficacy and safety in Chinese patients with advanced or recurrent non-squamous NSCLC.LY01008 combined with paclitaxel/carboplatin is expected to become a new treatment option for unresectable,metastatic,or recurrent non-squamous NSCLC patients in the first-line setting.
基金Science and Technology Bureau of Gansu Province,China(No.2019-0203-SFC-0207).
文摘Objective:To explore the effect of carbon ion radiotherapy(CIRT)on the bone marrow adjacent to or within the treatment fields,and to observe the bone marrow toxicities after CIRT alone.Methods:Twenty-one patients with malignant tumors of different body parts and treated with CIRT in Heavy Ion Center,Wuwei Cancer Hospital were analyzed retrospectively.The data of white blood cells,neutrophils,hemoglobin,platelets,lymphocytes and globulin before treatment,7,14 and 28 d during treatment,and 1 and 3 months after treatment were collected.Hematological toxicities were measured according to the Common Terminology Criteria for Adverse Events(CTCAE,Version 4.03)criteria.Dose-volume histogram parameters were obtained for all patients and analyzed for their correlation with myelosuppression.Univariate analysis was performed for patients’sex,age group,tumor site,radiation dose,and Karnofsky performance score(KPS)was used as an independent factor to find predictors factors for the risk of myelosuppression.Results:CIRT minimized the dose radiated to the bone marrow.Overall,volume receiving 3 GyE(V3)or more of the bone marrow were less than 0.5%,especially V5 less than 0.1%.No patients treated with carbon ion radiotherapy developed grade III or IV myelosuppression.Seven patients(33.3%)developed grade I myelosuppression and one patient(4.8%)developed grade II myelosuppression,and most of them showed reduced white blood cell counts.There were no significant differences in hemoglobin and globulin levels before and after CIRT.Univariate analysis did not find any statistically significant predictors for myelosuppression.Conclusions:CIRT is effective in preserving bone marrow function regardless of tumor site.Patients receiving CIRT alone have a low incidence of grade III myelosuppression and a mild effect on globulins.There was no significant correlation between occurrence of myelosuppression and the dose and site irradiated by CIRT.